Gapping up
In reaction to earnings/guidance:
- DAL +1.6% (guidance), ABCM +1.2% (guidance; also Starboard issues statement regarding the opportunity to maximize value at Abcam)
Other news:
- AEL +14.3% (receives acquisition proposal from Brookfield Reinsurance for $55.00 per AEL share)
- ACIU +12.1% (receives FDA fast track designation for anti-amyloid-beta active immunotherapy aci-24.060 to treat alzheimer's disease)
- CIR +6.9% (enters into amendment to definitive merger agreement with KKR (KKR) at $51/share)
- MOD +4.6% (Director sold $560K of stock)
- INSE +4.5% (signs contract extension with bet365)
- ALDX +3.9% (top-line results from the Phase 2 clinical trial of orally administered ADX-629)
- SSYS +3.5% (3D Systems (DDD) submits enhanced proposal to combine with Stratasys)
- TERN +3% (new preclinical data for TERN-601)
- EWTX +2.8% (positive 12-month topline results from ARCH open label study)
- IQ +2.2% (wins thirteen awards at the 2023 Shanghai TV Festival)
- VRNA +2% (submits NDA to FDA for Ensifentrine for the Maintenance Treatment of COPD)
- FREY +1.8% (announces key achievements ahead of capital markets day)
- EGLE +1.6% (Danaos Corporation (DAC) Delivers Letter to Eagle Bulk Shipping Board of Directors)
- LLY +1.6% (phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight )
- EU +1.4% (announces agreement for at-the-market offering)
- HOOD +1.3% (cutting 7% of its workforce according to WSJ)
- EXPI +1% (increases repurchase cap by $500 mln)
Analyst comments:
- GWRE +3.5% (upgraded to Buy from Hold at Stifel)
- K +2.5% (upgraded to Buy from Neutral at Goldman)
- SAIA +2.2% (upgraded to Outperform from In-line at Evercore ISI)